Inovio Pharmaceuticals (INO) Total Liabilities (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Total Liabilities of $43.7 million for Q1 2026, down 12.95% sequentially from $50.2 million in Q4 2025, and up 21.34% YoY from $36.0 million in Q1 2025.
Inovio Pharmaceuticals (INO) Total Liabilities (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $43.7 million in Q1 2026.
- Quarterly Total Liabilities rose 21.34% year-over-year to $43.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.7 million (up 21.34% YoY) and the FY2025 annual result came in at $50.2 million, up 12.35% from the prior year.
- Total Liabilities eased to $43.7 million in Q1 2026 per INO's latest filing, from $50.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $161.7 million in Q2 2022 and troughed at $33.5 million in Q3 2024.
- A 5-year average of $67.1 million and a median of $53.6 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities sank 60.63% in 2023, then surged 130.03% in 2025.
- Over 5 years, Total Liabilities stood at $126.2 million in 2022, then sank by 57.52% to $53.6 million in 2023, then retreated by 16.62% to $44.7 million in 2024, then advanced by 12.35% to $50.2 million in 2025, then dropped by 12.95% to $43.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $43.7 million, $50.2 million, and $77.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 10.03 Bn |
| 10 | Inovio Pharmaceuticals | 95.49 Mn | 95.49 Mn | - | 45.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.02 Mn |
| Mar 31, 2026 | 43.71 Mn |
| Dec 31, 2025 | 50.21 Mn |
| Sep 30, 2025 | 77.11 Mn |
| Jun 30, 2025 | 39.71 Mn |
| Mar 31, 2025 | 36.02 Mn |
| Dec 31, 2024 | 44.69 Mn |
| Sep 30, 2024 | 33.52 Mn |
| Jun 30, 2024 | 37.06 Mn |
| Mar 31, 2024 | 34.67 Mn |
| Dec 31, 2023 | 53.60 Mn |
| Sep 30, 2023 | 54.94 Mn |
| Jun 30, 2023 | 63.67 Mn |
| Mar 31, 2023 | 67.37 Mn |
| Dec 31, 2022 | 126.17 Mn |
| Sep 30, 2022 | 125.27 Mn |
| Jun 30, 2022 | 161.73 Mn |
| Mar 31, 2022 | 90.43 Mn |
| Dec 31, 2021 | 96.27 Mn |
| Sep 30, 2021 | 82.19 Mn |